Search
Brentuximab
go.drugbank.com/drugs/DB05471InvestigationalWe are collaborating with the National Cancer Institute (NCI) on three clinical trials of SGN-30 in combination with chemotherapy for the treatment of relapsed Hodgkin lymphoma, front-line ALCL and pediatric … SGN-30 received orphan drug designation from the FDA in July 2003 for Hodgkin lymphoma and in February 2004 for T-cell lymphomas.
Human papillomavirus type 31 L1 capsid protein antigen
go.drugbank.com/drugs/DB10310ApprovedInvestigationalHuman papillomavirus type 31 L1 capsid protein antigen is contained in Gardasil is a vaccine for intramuscular injection. … The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Type 31 which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae
Mixtures: GARDASİL 9 IM ENJEKSİYONLUK SÜSPANSİYON, 1 ADET ŞIRINGA+2 ADET İĞNEIodoform
go.drugbank.com/drugs/DB13813ApprovedInvestigationalVet approvedWithdrawnIodoform is soluble in fatty acids and decomposes releasing iodine in nascent state (96,7% of iodine) when in contact with secretions or endodontic infections [A32893]. … It is a relatively water-insoluble yellow solid that is chemically reactive in free-radical reactions [A32890].
Human papillomavirus type 33 L1 capsid protein antigen
go.drugbank.com/drugs/DB10311ApprovedInvestigationalHuman papillomavirus type 33 L1 capsid protein antigen is contained in Gardasil is a vaccine for intramuscular injection. … The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Type 33 which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae
Mixtures: GARDASİL 9 IM ENJEKSİYONLUK SÜSPANSİYON, 1 ADET ŞIRINGA+2 ADET İĞNEHuman papillomavirus type 45 L1 capsid protein antigen
go.drugbank.com/drugs/DB10312ApprovedInvestigationalHuman papillomavirus type 45 L1 capsid protein antigen is contained in Gardasil is a vaccine for intramuscular injection. … The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Type 45 which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae
Mixtures: GARDASİL 9 IM ENJEKSİYONLUK SÜSPANSİYON, 1 ADET ŞIRINGA+2 ADET İĞNEHuman papillomavirus type 58 L1 capsid protein antigen
go.drugbank.com/drugs/DB10314ApprovedInvestigationalHuman papillomavirus type 58 L1 capsid protein antigen is contained in Gardasil is a vaccine for intramuscular injection. … The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Type 58 which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae
Mixtures: GARDASİL 9 IM ENJEKSİYONLUK SÜSPANSİYON, 1 ADET ŞIRINGA+2 ADET İĞNECinoxacin
go.drugbank.com/drugs/DB00827ApprovedWithdrawnSynthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections.
Categories: Topoisomerase II InhibitorsMethoxyflurane
go.drugbank.com/drugs/DB01028ApprovedInvestigationalVet approvedWithdrawn(From AMA Drug Evaluations Annual, 1994, p180) In the US, methoxyflurane is one of the products that have been withdrawn or removed from the market for reasons of safety or effectiveness.[L43942] … An inhalation anesthetic. Currently, methoxyflurane is rarely used for surgical, obstetric, or dental anesthesia.
Teniposide
go.drugbank.com/drugs/DB00444ApprovedInvestigationalThis complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. … Accumulated breaks in DNA prevent cells from entering into the mitotic phase of the cell cycle, and lead to cell death. Teniposide acts primarily in the G2 and S phases of the cycle.
Categories: Topoisomerase II InhibitorsEdoxaban
go.drugbank.com/drugs/DB09075ApprovedInvestigationalIn addition to once daily dosing, the benefits over warfarin also include significant reductions in hemorrhagic stroke and GI bleeding, and improved compliance, which is beneficial as many patients will … It is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) and for the treatment of deep vein thrombosis (DVT) and pulmonary embolism